-
Canaud, G, Lopez Gutierrez, JC, Irvine, AD, Vabres, P, Hansford, JR, Ankrah, N, Branle, F, Papadimitriou, A, Ridolfi, A, O'Connell, P, et al.
Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)..
Genet Med
25(12)
:
100969
2023
view publication
-
Khuong-Quang, D-A, Nysom, K, Landi, D, Ziegler, D, Driever, PH, Leary, S, Bailey, S, van der Lugt, J, Perreault, S, Waanders, A, et al.
CTNI-37. CLINICAL ACTIVITY OF RAF INHIBITOR TOVORAFENIB ACCORDING TO PRIOR MAPK INHIBITOR TREATMENT IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY.
Neuro-Oncology
25(Supplement_5)
:
v82 -v83
2023
view publication
-
Nysom, K, Kilburn, L, Leary, S, Landi, D, de Vos-Kerkhof, E, Perreault, S, Witt, O, Ziegler, D, Driever, PH, Franson, A, et al.
CTNI-24. CLINICAL ACTIVITY AND SAFETY OF THE RAF INHIBITOR TOVORAFENIB IN PATIENTS WITH OPTIC PATHWAY GLIOMAS IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY.
Neuro-Oncology
25(Supplement_5)
:
v79 -v79
2023
view publication
-
Hansford, JR, Eisenstat, DD.
No safe harbors for recurrent posterior fossa group A ependymoma: A time for change in risk assignment?.
Neuro Oncol
25(10)
:
1868 -1870
2023
view publication
-
Ziegler, D, Lau, L, Khuong-Quang, D-A, Mayoh, C, Wong, M, Barahona, P, Ajuyah, P, Senapati, A, Nagabushan, S, Sherstyuk, A, et al.
Precision-guided treatment improves outcomes for children with high-risk cancers.
2023
view publication